Villarroel and colleagues (2011) described a pancreatic cancer patient that had a long-lasting response to mitomycin C (MMC, a crosslinking agent) treatment and whose tumor was deficient for PALB2 [61]. The gene discussed is PALB2; the disease is neoplasm.